Dianthus Therapeutics Bags FDA Permit to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
$DNTH
Biotechnology: Pharmaceutical Preparations
Health Care
Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of its Phase 2 Investigational New Drug (IND) application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy (MMN).